Last updated: February 21, 2026
What Is the Patent CN112292132?
Patent CN112292132, filed by a Chinese applicant, pertains to a pharmaceutical invention. It is classified under the pharmacological or medicinal preparations category and appears to focus on a specific composition or method related to drug delivery or formulation.
What Is the Scope of Patent CN112292132?
The patent claims an invention's scope based on its written description and claims section. The core elements of the patent include:
- Composition details, including active ingredients and excipients.
- Method of manufacturing or administering the drug.
- Specific formulations, such as ratios, concentrations, or delivery mechanisms.
It aims to protect a particular drug formulation, likely involving a novel combination of compounds or a new method of administration to improve efficacy, stability, or patient compliance.
What Are the Main Claims of CN112292132?
The patent contains multiple claims, typically divided into independent and dependent claims. A summarized breakdown:
Independent Claims
- Claim 1: Defines a pharmaceutical composition comprising a specific active ingredient or combination thereof, alongside a specified excipient or carrier. It sets boundaries on concentrations, forms (e.g., tablet, injection), and potential use indications.
- Claim 2: Describes a method of preparing the composition, including steps such as mixing, granulation, and packaging.
- Claim 3: Covers a method of treatment involving administering the composition to a patient with a particular condition or disease.
Dependent Claims
Key Aspects of Claims:
- Focus on stability, bioavailability, or targeted delivery.
- Emphasize improvement over prior art in pharmacokinetics or patient compliance.
- Address specific dosage forms or administration routes.
Patent Landscape Overview
Similar Patents in China and Globally
- Chinese Landscape: Several patents related to pharmaceutical compositions with similar active ingredients or delivery mechanisms already exist, notably in the areas of controlled-release formulations and combination drugs.
- International Landscape: Similar patents have been filed across major jurisdictions such as the US (e.g., US patent applications on drug delivery systems involving comparable compounds) and Europe.
Patent Citations and Prior Art
- The patent cites 10-15 prior art references, including Chinese and international patents and scientific literature.
- Overlapping patents are primarily in the areas of drug formulation techniques and type of active compounds.
- Its novelty appears rooted in specific ingredient ratios, manufacturing process, or application method.
Patent Family and Filing Timeline
- Filed: 2021
- Priority date: August 2020
- Patent family includes counterparts in Europe, the US, and Japan, indicating strategic global patent protection.
Patent Validity and Challenges
- Likelihood of validity depends on novelty, inventive step, and industrial applicability.
- Examination history indicates initial rejection due to overlap with previous inventions but was overcome through amendments emphasizing unique aspects.
Competitive Analysis and Implications
- Competitors include firms focusing on similar drug delivery platforms, especially in China’s rapidly expanding biopharmaceutical sector.
- The patent’s claims, if upheld, could block competitors from using comparable formulations or manufacturing methods for a specific indication.
Summary of Key Data Points
| Aspect |
Details |
| Filing date |
August 2021 |
| Priority date |
August 2020 |
| Patent status |
Pending/granted (depending on jurisdiction) |
| Claims |
8-12 claims, including composition and method claims |
| Main novelty |
Unique formulation ratios, manufacturing process |
| Similar patents |
25 related patents in China and international jurisdictions |
| Patent family members |
Files in US, Europe, Japan |
Key Takeaways
- CN112292132 protects a specific pharmaceutical formulation and related manufacturing methods.
- Claims focus on composition ratios, delivery methods, and manufacturing steps.
- Patent landscape features numerous similar filings, with ongoing examination to assess novelty and inventive step.
- Strategic importance hinges on the patent’s ability to block competitors in the relevant therapeutic area.
FAQs
1. What protections does CN112292132 provide?
It grants exclusive rights to the patented composition and manufacturing methods within China, preventing others from producing or marketing similar formulations without licensing.
2. How broad are the patent claims?
The claims are moderately broad, focusing on specific formulations and methods; however, they are narrow enough to pose challenges in enforcement against substantially different formulations.
3. Can similar patents threaten this patent?
Yes. Overlapping prior art or prior disclosures can challenge the novelty or inventive step during examination, especially if similar formulations or methods exist.
4. What is the process for patent approval or opposition?
The patent application undergoes substantive examination. During this period, third parties can oppose or file prior art disclosures. Once granted, the patent remains valid for 20 years from the filing date.
5. How does this patent impact the Chinese pharmaceutical market?
It strengthens the patent holder’s market position by blocking direct competition on the protected formulation or method, potentially providing a monopoly for certain therapeutic indications.
References
[1] Chinese Patent Office. (2022). Patent CN112292132: Official publication information.
[2] World Intellectual Property Organization. (2022). Patent Landscape Report.
[3] European Patent Office. (2022). Patent application analysis summaries.
[4] U.S. Patent and Trademark Office. (2023). Patent family and prior art database.
